Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or metastatic liver cancer.
Hepatocellular Carcinoma
DRUG: GC33(RO5137382)|DRUG: Sorafenib
Toxicity evaluation in accordance with CTCAE v3.0, Continuous|Dose limiting toxicity and maximum tolerated dose, Continuous
RECIST criteria (version 1.0) for response evaluation by CT/MRI in target and non-target lesions of HCC, every 2 months|Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib, Continuous
This is a Phase I open-label dose escalation study of GC33 in combination with Sorafenib in patients with advanced or metastatic HCC. This study is designed to evaluate safety, tolerability, pharmacokinetics, and efficacy. Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established.